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Endemic Mycoses and Allergies:
Diseases of Social Change
In 1950, the Biology Section of the New York Academy of Science
(NYAS) held what it claimed to be the ﬁrst conference on medical
mycology in the United States.1 What prompted the event was not the
announcement of the discovery of nystatin by Hazen and Brown, as
their publication was still in press, but the growing proﬁle of fungi and
fungal infections across the nation. Fungi, not least because of interest
in penicillin, were attracting the interest of biologists and biomedical
researchers who, alongside screens for antibiotic activity, were adopt-
ing them as experimental models in studies of nutrition, physiology
and immunology.2 All the leading names of the ﬁeld from the 1930s
attended the meeting: Carroll Dodge, Norman Conant, Rhoda Benham
and Lucille Georg, and there were new faces who had developed exper-
tise during the war and in particular localities. Speakers drew attention
to the increased incidence of systemic candidiasis, signalling a switch
in the medical mycological gaze from external (exogenous) to internal
(endogenous) disease. Although the incidence of endogenous, systemic
fungal infections was very low, they had very high mortality and pre-
sented unusual cases that fascinated physicians. In addition, there was
a new awareness of the toll of morbidity from endemic, exogenous dis-
ease, as with athlete’s foot and thrush, and with regionally speciﬁc, often
sub-clinical infections, principally coccidioidomycosis, blastomycosis
and histoplasmosis.
In this chapter, we tell the story of regionally speciﬁc fungal infec-
tions, and look at the rise of fungal-induced asthma, as one part of the
twentieth-century story of the rise of allergies and asthma.3 We begin
by discussing the new epidemiology of endemic fungal infections that
emerged in the late 1940s and the attempts by medical mycologists
and other interested clinicians to attract more resources for research,
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prevention and control. We discussed the increased incidence of acute,
invasive candidiasis associated with new medical treatments in the last
Chapter; here we examine in turn the three principal chronic, though
occasionally epidemic, regional mycoses prevalent in North America –
coccidioidomycosis, blastomycosis and histoplasmosis. Our attention
then switches to Britain and allergic fungal conditions, ﬁrstly, farmer’s
lung and then allergic bronchopulmonary aspergillosis (ABPA). This
class of fungal allergens was ‘discovered’ in Britain and seemingly absent
from North America, until expertise was transferred back across the
Atlantic.
The new epidemiology of fungal diseases
In the early 1950s, medical mycologists, along with cancer physicians
and chest surgeons, began to draw attention to a new problem posed by
invasive fungal infections. Writing in 1953, David Smith, a colleague of
Norman Conant at Duke Medical School described the new situation as
follows.
Unlike most bacterial and viral infectious diseases, the systemic
mycotic infections are not transmitted directly from patient to
patient; consequently, one would not expect to see epidemics caused
by fungi. In most instances the mycotic infections are endemic and
sporadic but true epidemics of sporotrichosis, coccidioidomycosis
and histoplasmosis do occur when groups of non-immune individ-
uals are exposed to an environment containing large amounts of
the saprophytic form of the fungus. More than a thousand cases
of sporotrichosis developed in the gold mines of South Africa when
the timbers in the mine became infected with Sporotrichum schenckii.
Epidemics of coccidioidomycosis occurred when companies of non-
immune soldiers from the East marched in the dust of certain South-
western deserts. Epidemics of histoplasmosis have occurred following
the exposure of groups of nonimmune individuals to pigeon manure,
chicken manure, bat manure in caves and to the dust of unused silos.4
Reviewing the epidemiology of fungal infections in the same year for
the New England Journal of Medicine, Otis Jillson pointed to ‘the recog-
nition of the benign, common forms of histoplasmosis; the diagnosis
and surgical treatment of coccidioidal pulmonary residua; the treatment
of blastomycosis with stilbenes’, and added the growing incidence of
systemic mycoses.5 Interestingly, he dealt with skin infections brieﬂy
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and said very little about exogenous or endogenous candidiasis, at a
time when nystatin was attracting attention.
At the 1950 NYAS meeting, Samuel B. Salvin, then at the Division of
Infectious Diseases at NIH, placed the incidence of fungal diseases in
context of other infectious diseases.
Fungus infections in man, although less frequent than bacterial, are
still numerically important. For example, of the 92,933 deaths due to
infections and parasitic diseases in the United States in 1945, 284, or
0.3 per cent, were due to mycoses. This was approximately equal to
the number of deaths reported as caused by scarlet fever, measles, or
the typhus-like diseases (due to rickettsia), and was more than the
total of all deaths recorded from rabies, smallpox, relapsing fever,
leprosy, brucellosis, paratyphoid fever, plague, cholera, and anthrax.
It should be realized, of course, that effective control measures are
employed against some of the aforementioned diseases, whereas con-
trol methods against the mycoses not only are not practiced, but,
generally, are not even known. It should also be borne in mind
that the dermatophytoses, although characteristically nonfatal, are
extremely common, probably equalling the most widespread of the
bacterial or virus diseases in prevalence.6
In 1953, Walter Nickerson from the Department of Microbiology,
Rutgers University, tried a creative presentation of mortality data to
chart the rise of fungal infections.7 He used graphs for the period
1945–1949 that showed starkly opposite mortality trends, where ‘all
infections’ had dropped sharply, while that from mycoses had increased
markedly. Nickerson had produced his graphic illustration by using very
different scales for the two classes of infection. Deaths from mycoses
were recorded as actual numbers, while those from all infections were
recorded in thousands. The alarming increase of nearly 50% in fungal
infection deaths was actually from 270 to 380, while the actual num-
ber of deaths from all infections had fallen 30%, from 93,000 to 66,000
deaths – still 170 times greater! In the event, the annual total deaths
from mycoses in the next decade never reached 500.8 More telling was
Nickerson’s point about morbidity; he stated that ‘mycotic infections
are probably the mostly widely distributed and most numerous types of
infection, with dermatophyte infections, such as athlete’s foot, alone as
prevalent as the most widespread of the bacterial and virus diseases’.9
Medical mycologists had long argued for recognition of the distinc-
tive pathogenicity of fungi. In 1940, Arthur Henrici, who worked in
the Department of Bacteriology at the University of Minnesota, argued
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that most bacterial and viral infections developed rapidly, and then
plateaued in severity, before falling away, because of either recovery or
death. With fungal infections, however, a typical pattern was of the slow
and incremental development of chronicity, and prolonged morbidity,
often at sub-clinical levels.10 The only bacterial diseases with similar
patterns of pathogenicity were tuberculosis and leprosy. Henrici main-
tained that the slow increase in severity meant either that the infecting
fungus progressively changed and developed pathogenic properties or
that the resistance of the host was gradually worn down. There was
no evidence of the former, so he focused on changes in the host and
its ‘soil’, claiming that prolonged exposure to certain fungi and their
toxins produced hypersensitivity in the host cells. Henrici referred back
to the theories of Richard Pfeiffer and Clemens von Pirquet on over-
active immune responses.11 Pfeiffer’s authority was drawn upon for the
argument that fungal endotoxins inﬂamed and ultimately killed cells,
creating a nidus for the fungus itself to grow. On the other hand, von
Pirquet’s work was used to suggest that host cells developed allergic-type
sensitivity. Henrici favoured the latter, but stressed that because fungal
infections were complex and variable, both mechanisms might operate,
or be found with different species of pathogen.
The prevalence of sub-clinical, chronic disease was recognised by
public health ofﬁcials as characteristic of regionally speciﬁc mycoses
in the United States. The new geography of endemic fungal infec-
tions was revealed by David Smith in 1953, on a map that showed
the distribution of coccidioidomycosis, blastomycosis and histoplasmo-
sis in the United States and northern Mexico12 (Figure 4.1). The new
epidemiological proﬁle changed the position of medical mycology in
the United States in the 1950s. This was evident ﬁrst in the prolifer-
ation of new publications and courses.13 Ana Espinel-Ingroff’s analysis
of the institutional development of medical mycology shows that new
departments and new experts emerged in affected areas, for example,
at Michigan State University (1951), Tulane University (1955), the Uni-
versity of California, Los Angeles (1956), the University of Oklahoma
(1957) and Virginia Commonwealth University (1965).14 Initiatives took
place in varied settings, sometimes with public health departments, but
mostly in university biology and microbiology departments. That said,
leading ﬁgures and departments in the East remained important. Nor-
man Conant, Chester Emmons and Libero Ajello continued to head
key departments at Columbia, Duke and the National Microbiological
Institute, which was reorganised from 1955 as the National Institute of
Allergy and Infectious Diseases (NIAID) and, of course, the Centers for
Disease Control and Prevention (CDC) in Atlanta remained inﬂuential.
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Figure 4.1 Distribution of histoplasmosis, blastomycosis and coccidioidomy-
cosis in North America.15 The histoplasmosis areas are shown in black, the blasto-
mycosis as circles and the coccidioidomycosis areas as triangles. Smith, D. T., ‘The
diagnosis and therapy of mycotic infections’, Bull NY Acad Med, 1953, 29(10):
778. This ﬁgure © 2013 New York Academy of Medicine used under Creative
Commons Attribution – Non-commercial licence: http://creativecommons.org/
licenses/by/3.0/
Regional mycoses I: ‘Valley fever’ – coccidioidomycosis
The ﬁrst regionally speciﬁc infection to attract attention was coccid-
ioidomycosis through Emmons’s work at NIH.16 The very notion of the
geographically speciﬁc infection had weakened in medicine in the sec-
ond half of the nineteenth century with the move towards aetiological
deﬁnitions of disease and the essential role of speciﬁc germs. However,
there was new interest in the early twentieth century with vector-borne
tropical diseases, where the range of insects was limited by biogeograph-
ical factors.17 In the United States this was evident in the work on
tick-borne Rocky Mountain Spotted Fever, which had its highest preva-
lence in certain states: North Carolina, Oklahoma, Arkansas, Tennessee,
and Missouri.18
In the 1940s, coccidioidomycosis, also styled as ‘San Joaquin’ or
‘Valley fever’, was known to be caused by the fungus Coccidioides immitis
(C. immitis).19 Its mode of spread was seemingly simple: fungal spores,
released from the soil, entered the body through the lungs, where an
infection might develop. In fact, most people did not develop any
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symptoms and those that did experienced a cold or mild ﬂu-like symp-
toms. In a tiny fraction of people, especially those with other diseases
and with weakened immune systems, infection spread through the
bloodstream to give disseminated coccidioidomycosis.
Research by Ernest C. Dickson and Charles Smith in the 1930s had
revealed that infection with C. immitis was very common amongst those
living in certain areas, and that it was best regarded as an endemic,
chronic and benign infection.20 It seemed that residents built up immu-
nity from long-term, low-level exposure, hence most infection was
sub-clinical and, as would be expected, clinical disease was most com-
mon amongst in-migrants who had not had the opportunity to build up
immunity. Population movement and settlement westwards had been
going on in the United States for many decades and it seemed likely
that coccidioidomycosis emerged at this particularly moment because
of the new speed and scale of migration, especially families ﬂeeing dust
blows in the prairies. Evidence to support this view came in the 1940s
when coccidioidomycosis developed amongst the recruits brought to
the region to train for the United States Air Force.21 As the war effort
grew, more troops arrived, which gave investigators the opportunity
to make comparisons of incidence by sex, race and nationality. For
instance, some 13,000 German prisoners of war were held at Florence,
Arizona, where the incidence of coccidioidomycosis became so high
that they were moved away, as United States government ofﬁcials wor-
ried that such a high rate of infection would lead to them being
charged with violation of the Geneva Convention on treatment of war
prisoners.22
After the war, the military presence in the Southwest continued and
expanded. So too did worries about coccidioidomycosis and this led
in 1955 to the establishment of an annual meeting of the Veterans
Administration-Armed Forces Coccidioidomycosis Cooperative Study
Group (CCSG). This type of cooperative meeting had begun in the late
1940s as a way of developing and sharing expertise on the treatment of
tuberculosis with streptomycin.23 Initially, the main agencies were the
Veterans Administration, the Army, the Navy, Public Health Services and
the National Research Council. While the focus of the early annual con-
ferences was squarely on tuberculosis, fungal infections were sometimes
discussed, as in 1952 when trial coordinators noted that histoplasmosis
lung infections had complicated their clinical trials by making differen-
tial diagnosis with X-rays more difﬁcult.24 The ﬁrst coccidioidomycosis
meeting in 1955 came from a direct concern with the growing inci-
dence of the infection, especially at air bases, notably Williams AFB
104 Fungal Disease in Britain and the United States 1850–2000
and Luke AFB in Arizona, Edwards AFB in California, and Lemoore NAS,
also in California. The problem grew with the investments in military
infrastructure that came with the Cold War. Williams and Luke became
training centres, with a steady stream of non-immune recruits passing
through, while Lemoore was further developed in the 1960s for strike
aircraft, and Edwards became a centre for research, including rocketry,
and eventually was a landing site for the Space Shuttle.
The construction of new runways and other facilities on these mil-
itary sites disturbed the subsoil, which together with aircraft take-offs
and landings circulated C. immitus spores to those living and working
nearby.25 Some civilian sufferers were treated by military doctors; how-
ever, they were mostly dealt with by local physicians, who also treated
military personnel when they were referred to local hospitals for sero-
logical and radiological investigation. Thus, the leading authority on
the disease in the military, from the 1940s to the 1960s, was Charles E.
Smith, Dean of Public Health at the University of California Berkeley.26
He had developed his expertise during the Second World War at Berke-
ley, where he established a research laboratory and diagnostic serological
services.
In the 1950s C. immitus biology was found to be more compli-
cated than previously recognised and the new understanding was set
out in the ﬁrst book entirely on the disease by Marshall J. Fiese in
1958.27 Fiese was based at the Veterans Administration Hospital in
Fresno and in his ‘Foreword’ to Fiese’s volume, Charles Smith wrote
that the work reﬂected the author’s deep experience: ‘[Fiese] has seen
and viewed . . . . countless roentgenograms[X rays], seen and studied the
tragic autopsies, and perhaps most importantly of all, lived for years
in the coccidioidal countryside.’ An unusual feature of C. immitis was
that, rather than being spread by spores, it was actually the cells of the
hyphae, called conidia, that circulated in the air. Conidia were found
to be tiny and readily carried in dust; hence, the popular represen-
tation of coccidioidomycosis as spread by ‘ﬂying conidia’, or ‘ﬂying
chlamydospores’.28 When inhaled, the human body was shown to
respond in one of three possible ways. First and most commonly, the
conidia were destroyed by the immune system and a degree of immu-
nity, albeit variable, to future infection was established. Alternatively,
the conidia grew in the lungs in a spherical form, into bodies that
released many more such ‘spherules’, producing inﬂammation and a
chest infection. Lastly and least common, and only if the lung infection
was severe, infection could spread in the blood and cause inﬂammation,
especially in the skin and brain. The reported incidence of the severe
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form increased in the 1960s and was found principally amongst patients
and former patients who were to some degree immuno-compromised.29
Local physicians in Arizona and California had mostly to deal with
the second type of endemic infection, which was often self-limiting.30
Particular occupational groups were at higher risk of developing the dis-
ease, notably, agricultural and construction workers. Archaeologists were
another high-risk group, and often had severe infection because they
were new to a region. The proﬁle of coccidioidomycosis rose in spo-
radic epidemic outbreaks, as in California at the end of 1977. A large
dust storm blew through Bakersﬁeld on 20 December, depositing coni-
dia to the north and west along familiar terrain in the San Joaquin
Valley.31 Cases were reported in two main areas: the known endemic
area of Kern County around Bakersﬁeld and a previously non-endemic
area west of Sacramento. Within six months, 142 cases of clinical lung
disease had been identiﬁed in Kern County and 379 at the University
of California Davis (UCD), nearly 300 miles north, with sufferers from
Los Angeles and Oakland, as well as Sacramento. Public health ofﬁ-
cials reported that rainfall immediately after the storm had probably
reduced signiﬁcantly the number of cases; however, they worried that
conidia had drained into the subsoil and that new endemic areas might
be created.32 Demosthenes Pappagianis, a member of the Department of
Medical Microbiology at UCD who had led the local response to the epi-
demic, became a leading researcher on the epidemiology of the disease
in subsequent decades33 (Figure 4.2).
In the early 1990s, there was another epidemic, later termed ‘the great
coccidioidomycosis outbreak’. Reported cases of the infection rose from
a long-term average of 300–600, to 1,200 in 1991, to 4,541 in 1992
and 4,107 in 1993.34 The foci were in the south of the San Joaquin
Valley in Kern and Tulare counties. Pappagianis was brought in to
investigate. He found no obvious precipitating reason for the outbreak,
and instead looked to climatic factors, notably the long-term drought
and high spring rainfall in 1991 and 1992, to soil disturbance from
construction; and to possible new groups of susceptible in-migrants.35
The outbreak brought national attention to coccidioidomycosis and
a CDC-led investigation, whose interest was in both endemicity and
the extent of acute and disseminated disease.36 Their study concluded
that with the aging of the US population and the increase in the
number of immunosuppressed persons, severe pulmonary and dissemi-
nated coccidioidomycosis threaten to become important public health
problems in areas of endemicity.37 Pappagianis also contributed to an
investigation of an outbreak following an earthquake in Northridge,
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Figure 4.2 The geographic distribution of coccidioidomycosis. Cross-hatching
indicates the heavily disease-endemic area, single hatching and the moderately
disease-endemic area.38 Kirkland, T. N. and Fierer, J., ‘Coccidioidomycosis:
A reemerging infectious disease’, Emerg Infect Dis [serial on the Internet].
1996, Sep. Available from www.nc.cdc.gov/ncidod/eid/vol2no3/kirkland.htm
DOI: 10.3201/eid0203.960305. CDC Public domain material.
California in January 1994, to which 203 cases were linked and three
coccidioidomycosis deaths added to the overall toll of 57.39
In addition to Pappagianis, two other researchers stood out in the
study of coccidioidomycosis during the period. One was John Galgiani,
who worked at the Veterans Affairs Medical Center and University of
Arizona, Tucson, and was the leading expert on coccidioidomycosis in
that state. His specialism was immune responses and he was amongst
the ﬁrst to publish on coccidioidomycosis in AIDS sufferers.40 Over
many years he campaigned for recognition that coccidioidomycosis was
becoming a disease of national importance, because of continuing high
rates of in-migration to Southwestern states and the increase in the
number of immunosuppressed patients. General population mobility
was also a factor, with many cases presenting outside of endemic areas
in out-migrants; indeed, he reported that 46% of coccidioidomycosis
patients with AIDS were in non-endemic areas.41 In 1996, coccid-
ioidomycosis was being discussed as ‘a re-emerging infectious disease’.42
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Theo Kirkland and Joshua Fierer, respectively, from the San Diego
School of Medicine and Department of Veterans Affairs Medical Cen-
ter, San Diego, wrote that it warranted the label because ‘the number
of cases . . .has increased dramatically, and the clinical symptoms of
this illness have changed in patients with acquired immunodeﬁciency
syndrome (AIDS)’.43
The second key researcher was David A. Stevens, who was based in the
Santa Clara Valley Medical Center, San José and the Stanford University
School of Medicine. He became a leading authority on the clinical man-
agement of coccidioidomycosis, especially the use of chemotherapy. His
expertise, developed along with that on the treatment of aspergillosis
and other opportunistic mycoses, was recognised in leadership roles and
honours in the Medical Mycological Society of the Americas (MMSA),
International Society for Human and Animal Mycology (ISHAM) and
the American Society for Microbiology (ASM). Stevens’s early career
work was on viruses, but he switched to fungi in 1974 with a study
of immunity to C. immitis and then to its treatment.44 With Hillel
B. Levine, he pioneered the use of one of the new azoles, micona-
zole, for coccidioidomycosis.45 In 1980, he edited a new textbook on
the disease, contributing chapters on immunology, other syndromes,
immuno-compromised hosts, chemotherapy immunotherapy, vaccina-
tion and a bibliography.46 Stevens enrolled Pappagianis to write on
epidemiology and serology, and Galgiani on ophthalmic disease.
By the 1970s, the Cooperative Study Group meetings, which began
under military sponsorship, had moved to civilian control, with Stevens,
Galgiani and Pappagianis taking leading roles. However, as early as 1957
a larger symposium had been called and that met every eight years
or so, styling itself as ‘international’ for the ﬁrst time when it met in
Tucson in 1977.47 This change reﬂected two developments: ﬁrst, greater
interest in the disease in Mexico and South America and second, the
experience of physicians across borders with serological diagnosis and
amphotericin B treatment of disseminated disease.48 Furthermore, after
the Californian coccidioidomycosis outbreak in 1977, a growing num-
ber of laboratories had begun to explore vaccine development, utilising
the tools of the new molecular biology.49 Indeed, a vaccine developed
by Pappagianis and Levine went on trial in 1981, but this showed little
or no beneﬁt.50 Attention was also directed to ethnic and social groups
that were at greater risk from the disease, particularly black men, Native
Americans, and pregnant women. With the former, researchers explored
the contribution of racial susceptibility and environmental factors, with
a consensus developing around the importance of the latter.
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Researchers found that exposure, socio-economic position and access
to health care were the most important determinants of vulnerability
to infection and the development of disease.51 Pregnant women were
thought to be vulnerable because of changes in their immunity and hor-
monal levels, but close study showed them to have, at worst, only a tiny
additional likelihood of developing disseminated disease.52 In the 1980s,
as would have been expected, more coccidioidomycosis was reported in
immuno-compromised patients in Southwestern states, and also across
the United States in people who had lived or travelled to the endemic
areas. Thus, the work of regional coccidioidomycosis experts linked up
with that of mycologically minded clinicians nationwide. Their research
and clinical experience put them in a good position to assume national
leadership roles in the ﬁeld. For example, David Stevens led the NIH
multicentre clinical trials group on antifungal drugs between 1990 and
2000 and chaired committees writing practice guidelines on aspergillosis
as well as coccidioidomycosis.53
Regional mycoses II: Blastomycosis – North American
and otherwise
Blastomycosis was a term invented at the end of the nineteenth cen-
tury for eruptive skin lesions or granulomas, which were assumed to
be caused by infective fungi. The preﬁx ‘blasto-’, from the Greek for
‘budding’ or ‘sprouting’, came from the clinical presentation of raised
lesions that were disﬁguring, especially so with facial lesions. In the
1900s in the United States, the name became associated with so-called
Gilchrist’s disease, ﬁrst thought to be protozoan, but then linked to a
dimorphic (two forms) fungus named Blastomyces dermatitidis (B. der-
matitidis).54 For a while the infection was termed ‘North American
blastomycosis’ as researchers found that it was restricted to the geo-
graphical areas of the Ohio, Mississippi and Missouri River basins and
the western shore of Lake Michigan. There followed, what contempo-
raries recognised as, ‘an era of confusion during which the disease was
confounded with other entities, particularly cryptococcosis and can-
didiasis’ and ‘Nineteen new names were suggested for the causative
fungus.’55 Consensus on the pathogenesis of the disease followed work
by Norman Conant and colleagues at Duke Medical School in the late
1930s.56 They endorsed the idea that there was a form of the disease
speciﬁc to North America, though other forms of blastomycosis, due
to other fungal species, were found on other continents. South Ameri-
can blastomycosis was a condition with similar symptoms, but produced
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by a different fungus – Paracoccidioides brasiliensis. Although blastomy-
cosis typically ﬁrst presented as skin lesions, there were many reports
of disseminated disease, which suggested parallels with coccidioidomy-
cosis. Doctors wondered if there was also self-limiting or sub-clinical
pulmonary infection; however, there was no evidence of aerial transmis-
sion in the mode of C. immitis. There were few reports of blastomycosis
fungus in the environment, and certainly none of concentrations likely
to produce disease in humans. The mystery of the manner in which it
spread led some doctors to call it the ‘the enigmatic disease’.57
A study in the mid-1960s by Leo Furcolow, who was based in Kansas
in the centre of an endemic area, showed that there had been only 685
conﬁrmed cases of blastomycosis across ﬁve states between 1912 and
1964, a ﬁgure which he assumed grossly to under-estimate its actual
incidence.58 Furcolow found that infection rates were higher in males
than females, and there was ‘a slight excess of cases among Negroes’;
both factors were linked to the view that blastomycosis was associated
with outdoor work or sports. A similar geographical distribution of the
incidence of B. dermatitidis was found in dogs, so perhaps they were
hosts and further credence to this link was suggested by similarities
with the epidemiology of histoplasmosis. Another difﬁculty in mapping
the disease, certainly in comparison with coccidioidomycosis, was the
absence of a reliable skin test, which meant that the epidemiological
picture relied on symptomatic cases.
Disseminated blastomycosis attracted the attention of clinicians
because of its high mortality rate, which was typically 80%, though
treatment with amphotericin B brought this down to less than 20%.59
A difference with other endemic fungal diseases was that immunosup-
pressed patients were seemingly less likely to become infected, though
if they did, severe disease was common.60 Epidemiological and clinical
studies found no signiﬁcant patterns in the incidence of blastomyco-
sis, other than predisposing illness. However, it has been always been
more common in men, seemingly because of outdoor exposure. Suspi-
cions remained that its epidemiology was similar to coccidioidomycosis
because the lungs were the primary site of infection, and its prevalence
amongst in-migrants and construction workers.61
The low incidence of endemic blastomycosis, along with the limited
systemic infection, meant that no critical mass of local specialist prac-
titioners developed and the expertise of the few people with special
knowledge was not in demand. However, scientists and clinicians in the
regions affected were able to develop specialist practices by developing
work on other low-level endemic mycoses, most notably histoplasmosis.
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Regional mycoses III: Histoplasmosis62
Histoplasmosis is caused by infection with the fungus Histoplasma cap-
sulatum (H. capsulatum), and is associated with speciﬁc localities; indeed,
it was sometimes referred to as Ohio Valley Fever, though it soon
became clear its prevalence was wider. Its endemic areas overlapped with
those of other regional fungi and researchers’ work straddled different
mycoses. For example, Leo Furcolow became renowned for his work on
blastomycosis and histoplasmosis, and Louis Ajello combined expertise
on coccidioidomycosis and histoplasmosis.63 However, unlike blastomy-
cosis, whose low incidence meant less attention from the clinicians,
histoplasmosis, similar to the medical history of coccidioidomycosis,
gained prominence nationally as social changes led to an increase inci-
dence and importance. Moreover, according to Thomas Daniel and
Gerald L. Baum, a national research network emerged around the dis-
ease with work led by federal agencies.64 For Daniel and Baum, one key
ﬁgure in the United States was Jan Schwarz, a Jewish émigré based in
Cincinnati, Ohio, who worked on tuberculosis, before taking Conant’s
course at Duke and converting to mycology. From his base in Cincin-
nati, at the centre of the H. capsulatum endemicity, he became a leading
national expert alongside his friend Leo Furcolow, who became known
as ‘Mr Histoplasmosis’.
Retrospectively, the ﬁrst case of histoplasmosis has been identiﬁed in
the Panama Canal Zone in 1906, when Samuel Taylor Darling reported
an acute lung infection, with fever and breathlessness, caused by a pro-
tozoan that he named Histoplasma capsulatum.65 Sporadic cases were
reported over succeeding decades and in 1934 its causal organism was
shown to be a fungus rather than a protozoan.66 However, the disease
only attracted the attention of doctors in the 1940s in relation to pul-
monary tuberculosis, ﬁrst in the military and then after the war in
sanatoria. Recruits for the military were screened for pulmonary tuber-
culosis, with both a chest X-ray, which revealed active or healed lesions
in the lungs, and the tuberculin skin test, which through an immune
response conﬁrmed either active or previous infection. A signiﬁcant
number of recruits showed, perversely, lesions in the lungs with a neg-
ative skin test. One possibility was that immunity declined over time;
another was that a second disease was causing the lung lesions, and it
turned out that histoplasmosis was such a disease. Fortuitously, a means
to investigate the matter became available with the development of a
tuberculin-type skin test for the infection, using an antigen product
called histoplasmin. One study showed that of 94 men with healed lung
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lesions, 24 cases were due to tuberculosis and 70 to histoplasmosis.67
A later study by Furcolow, published in 1962, showed that histoplas-
mosis was responsible for lesions in 7.5% (3,366/44,882) of sanatorium
patients from across the country, which indicated that nationally some
8,200 patients entered sanatoria with evidence of histoplasmosis, and
that of these, 25% might have had active disease with tuberculosis.68
This work, facilitated by the Division of Mycotic Diseases at CDC and
the US Veterans Administration, and orchestrated through a Coopera-
tive Study Group from 1952, revealed three features of histoplasmosis.
First, it showed that there were certain regions of the United States
where infection with H. capsulatum was very common, but that the
development of symptomatic disease was quite rare. It seemed that
children living in endemic areas developed immunity from low-level
exposure and that this gave long-term protection. Thus, those likely to
develop illness were adult in-migrants without previous exposure.
Second, research on the aetiology of the infection was inconclusive
for many years, but eventually yielded that the main source of infec-
tion was soil dust and that localities with accumulations of bird and bat
droppings were particularly pathogenic. At times, histoplasmosis was
known as ‘cave disease’. Daniel and Baum describe the ‘detective story’
by which the aetiology was solved. Their narrative begins with a case at
Camp Gruber in March 1944 when the soil as a source of the fungus was
ﬁrst indicated, but they show that it took several decades to determine
a speciﬁc aetiology.69 Nonetheless, greater medical awareness of histo-
plasmosis and improved serological diagnostic testing led to more cases
being identiﬁed, especially of systemic infection where, as with similar
invasive mycoses, amphotericin B was the treatment of choice.70
By the 1970s, the disease had gained a higher proﬁle, as increased pop-
ulation mobility around the United States brought more non-immune
people to endemic areas, while anyone with active infection who moved
anywhere across the country and became immuno-compromised was
vulnerable to severe infection. There were also a series of epidemic out-
breaks, often with small numbers affected and typically quite localised,
but they were unusual, even bizarre, and attracted press and medical
attention. Daniel and Baum discuss three epidemics: Mason City, Iowa
in 1962 (returning in 1964) which was traced to bird rookeries; Suwanee
County, Florida in 1973, linked to bats; and, the biggest of all, Indi-
anapolis in 1978, which returned two years later.71 Final estimates for
the Indianapolis outbreak were that 120,000 people were infected, with
448 persons developing clinical illness, 55 with severely disseminated
disease and 19 deaths. Over the 1980s and early 1990s, histoplasmosis
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became associated in the public mind and amongst physicians with
AIDS, being the commonest endemic mycosis affecting patients.72 Sur-
veys in the early 1990s showed that it was found in 2–5% of AIDS
sufferers in endemic areas and was the ﬁrst sign of infection in over half
of these cases. Infection rates amongst AIDS patients as high as 25% were
found in certain cities, notably Indianapolis, Kansas City, Memphis and
Nashville. Patients had quite general symptoms and treatments with the
new forms of amphotericin B were successful, though maintenance of
antifungals, typically the new azoles, was essential to prevent relapse.
Farmer’s lung and allergic bronchopulmonary
aspergillosis (ABPA)
Unlike the United States, Britain had no regionally speciﬁc mycoses
linked to environmental factors of soil and climate, however, there
were geographically localised conditions linked to occupation, which
emerged in the 1950s. The most important was farmer’s lung, which
was initially linked to the Aspergilli fungi and pulmonary aspergillosis.73
Aspergillosis, the principal cause of which was Aspergillus fumigatus
(A. fumigatus), was considered only at the very end of Henrici’s ency-
clopaedic Molds, Yeasts and Actinomycetes in 1930, after coccidioidomy-
cosis, dermatophytosis, American blastomycosis, histoplasmosis and
sporotrichosis.74 However, the 15th edition of Taylor’s Practice of Medicine
in 1936 presented aspergillosis as an occupational disease of handlers of
birds and grain, along with those who sorted human and animal hair
for various products, for example, wigs.75 Also in 1936, Richard Fawcitt,
a radiologist in Ulverston, Cumberland, discussed Aspergilli spp. as the
main cause of broncho-mycosis in the local farming community.76 The
numbers affected were small, but this study and one by Fawcitt’s col-
league Munro Campbell, are seen in hindsight as the beginning of the
recognition of ‘farmer’s lung’ as an occupational disease.77 Fawcitt had
also found aspergillosis amongst housecleaners, which might have been
linked to new domestic technologies, such as the vacuum cleaner, which
spread spore-carrying dust from exhaust vents.78
By the end of the 1930s, fungal spores had been added to pollen
and house dust as causes of asthma, the prevalence of which was ris-
ing and fascinating doctors because of its complex aetiology, variable
presentation, and link between the physiological and the psychologi-
cal. At this time the physical basis of asthma was discussed in terms
of allergic, hypersensitivity states, where the body reacted abnormally
to certain substances or ‘allergens’.79 The largest group of allergens was
plant and animal matter in the environment, with pollen and aerial
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dust understood to be the main exciting causes of allergic symptoms.
Doctors debated whether the increased prevalence was due to better
recognition, or because modern lifestyles made the body more vulner-
able and increased exposure to allergens, or because new allergens had
been created by modern farming and industry. In 1936, Grafton Brown,
a Washington physician who specialised in allergy, pointed out that
fungal spores were ubiquitous, present throughout the atmosphere in
huge numbers and much smaller than pollen grains.80 He was surprised
that researchers had not considered them as allergens in house dust,
especially when scientists were familiar with fungi as contaminants of
their culture plates and slides in microbiology laboratories. According
to Charles Thom and Margaret Church, writing in 1926, ‘the Penicillia,
the Aspergilli and the Mucors are the weeds of the culture room’ and,
of course, one now celebrated incidence of fungal contamination led
to the discovery of penicillin.81 Surveys of aerial allergens increased in
the 1930s, using aeroplanes to explore high altitudes and remote loca-
tions, including ﬂights by Charles Lindberg to survey areas in northern
latitudes.82 While the spores of a large number of fungal species were
found to be potential allergens, they ranked well below pollen and dust.
levels of known fungal disease spores found in the atmosphere were well
below those of Alternaria, an ascomycete species that caused disease in
plants and which emerged as main fungal suspect in causing asthma
attacks.83 Next in importance were the Aspergilli.
In Britain, aspergillosis was discussed in detail in James Duncan’s
national survey of fungal disease in 1945, in relation to both pulmonary
disease and farmer’s lung.84 With pulmonary disease, cases were few and
far between, and difﬁcult to diagnose because of confusion with tubercu-
losis. However, Duncan was clear that ‘the fungus is an essential factor
in the aetiology of farmer’s lung’, but doubted that it was a primary
inﬂammatory agent.85 In 1953, Thomas Studdert, an assistant physician
at the Cumberland Hospital in Carlisle, contested earlier views,
The currently quoted view that farmer’s lung is an actual fungous
(sic) infection of the lungs does not bear close examination. The
explosive onset, spontaneous clearing, and radiological picture are
totally unlike any true fungous disease, and no real evidence has been
produced to support this theory.86
Studdert’s alternative, still framed with the possibility of fungal involve-
ment, was that farmer’s lung was an allergic reaction ‘to some material in
the fungus-laden dust’.87 By the mid-1950s, the number of fungi consid-
ered as allergens increased to include Penicillia, Mucors and other genera,
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yet their role was now seen as creating allergenic dust, or mechanical
irritation of the bronchi and alveoli, rather than speciﬁc allergic reac-
tions. A 1963 report by the British Industrial Injuries Advisory Council,
that led to the scheduling of a variety of occupational lung condi-
tions, linked farmer’s lung to other ‘dust diseases’, such as thresher’s
lung, chaff cutter’s lung and bagassosis (sugar cane handler’s disease).88
It maintained the association with mouldy hay and vegetables, but said
nothing about the role of speciﬁc fungi.89
A key reason why Aspergilli spp. were dropped from discussions of
asthma and occupational diseases in the 1960s was the creation of the
new speciﬁc condition of ABPA.90 In 1952, Kenneth Hinson, with col-
leagues at the London Chest Hospital, published a study of eight cases
of pulmonary aspergillosis, three of which were said to be an allergic
type previously unrecognised and ‘caused by sensitization of the host
to the fungus’.91 The condition was characterised around several symp-
toms: a syndrome of recurrent fevers, a changing X-ray pattern showing
progressive lung damage, peripheral blood eosinophilia, and purulent
sputum containing the A. fumigatus. Hinson and his colleagues were
seen to have described an unusual type of aspergillosis, itself still very
rare, so their claim was neither challenged nor endorsed; but it remained
on the record. ABPA, as it was later styled, was not characterised by
the invasive growth into tissues, rather fungi simply grew in pulmonary
ﬂuids and on the surface of lung tissues, causing inﬂammation.
ABPA attracted increasing attention in Britain through the 1950s and
1960s as doctors dealt with more patients with chronic lung diseases.
It is again a moot point whether the decline in the incidence of pul-
monary tuberculosis revealed previously submerged diseases, or whether
the spectrum of disease that now faced doctors was genuinely new. Over
the 1960s, there was increased incidence of lung cancer, chronic bron-
chitis and emphysema, which were linked to the effects of cigarettes,
smoke pollution and occupation diseases. The growing incidence of
non-speciﬁc chronic lung disease was captured in 1962 in the creation of
the new, condition of chronic obstructive pulmonary disease (COPD).92
In both the United States and Britain there was more research on occu-
pational diseases, which led to a greater differentiation of causes, linked
to improved prevention and new regulations.93 However, ABPA was only
reported in Britain and particularly in London, where the concentra-
tion of patients with chronic chest conditions allowed Jack Pepys, who
was one of Britain’s leading experts on allergies, to report new ﬁnd-
ings in 1959. He had investigated 145 patients who had A. fumigatus
in their sputum, ﬁnding that 16 exhibited ABPA, according to Hinson’s
1952 criteria.94 Pepys published a second study in 1969, in which
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he reported on 111 patients.95 He wrote that the primary indicators
of ABPA were transitory pulmonary shadows, eosinophilia of blood
and sputum, evidence of allergy to A. fumigatus and fungal mycelia in
sputum. Corticosteroids were the recommended therapy, having been
shown to be more effective than bronchodilators and other symp-
tomatic treatments. The condition was typically debilitating, leading to
progressive deterioration in lung function, though in some patients the
condition ‘burnt out’ and they ‘recovered’.
American allergists and pulmonary specialists were curious about why
ABPA was not found across the Atlantic. In 1969, Raymond Slavin and
colleagues at the St. Louis University School asked:
Why is [allergic] aspergillosis such a rarity in the United States?
It would seem that the climate and geography of England does not
make a profound difference since A. fumigatus is commonly reported
in air sampling surveys in this country. In addition, as stated previ-
ously, secondary aspergillosis is not uncommon. It appears then that
a failure of recognition and errors of omission account for the rarity
of allergic aspergillosis in the United States . . .With the proper appre-
ciation of the characteristics of allergic aspergillosis, both laboratory
and clinical, this disease may be more frequently recognized and
take its place with such hypersensitivity pneumonitides as pigeon
breeders’ disease, bagassosis and farmers’ lung.96
As late as 1977, APBA was being discussed as an ‘emerging disease’ in the
United States, due ‘to increased awareness by physicians, increased refer-
ral, better diagnostic modalities, and earlier bronchography’.97 Stud-
ies in the 1970s comparing the incidence of APBA in London and
Cleveland showed similar levels of sensitivity to A. fumigatus antigens
in asthmatics in both cities (23% and 28%, respectively), with the dif-
ferences in prevalence attributed to exposure.98 However, the incidence
of the condition was on the rise in both countries, contributing to
the overall increase in asthma, which has been widely discussed and
attributed to many factors, from greater awareness to modern lifestyles.
ABPA was soon recognised in most countries as the most common form
of fungal-induced allergic lung disease and, though a largely chronic
condition, was known to produce acute episodes.99
By the early 1980s, ABPA was a disease deﬁned by eight diagnostic cri-
teria, which were: asthma, an immediate positive skin test to Aspergillus
antigens; presence of antibodies for A. fumigatus; elevated total serum
immunoglobulin E (IgE); bronchial damage revealed by X-ray; high lev-
els of white blood cells; proximal dilatation of the bronchi and elevated
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serum immunoglobulin levels of IgE-Af and lgG-Af compared with
mould-sensitive asthmatic patients.100 This demanding series, which
combined clinical, X-ray, laboratory and functional criteria, meant that
differential diagnosis against other lung conditions, such as pneumo-
nia, bronchiectasis and carcinoma, was difﬁcult in practice. There were
problems about standardisation between individual clinicians, let alone
across clinics and countries. Treatment was largely symptomatic, mostly
with prednisone, an anti-inﬂammatory corticosteroid; however, some
doctors tried antifungal antibiotics, given by inhalation and as well as
systemically.101 The chronic character of ABPA led to investigations into
the degree of the destruction of lung tissue in severe cases, recognition
of which led eventually to the designation, by David Denning and his
colleagues in Manchester, of a group of patients with the new condition
of severe asthma associated with fungal sensitivity (SAFS).102
By the early 1990s, ABPA was mainly identiﬁed with two groups:
chronic asthma sufferers and people with cystic ﬁbrosis. In both groups,
inﬂamed lung tissues, accumulated exudates, dilated bronchi, impaired
breathing and other factors created the conditions for Aspergilli to grow
and prompt an allergic response. Epidemiological studies suggested that
1–5% of asthma sufferers were affected by ABPA, which was, of course,
a fast growing number of individuals. In 1991, the American Academy
of Allergy, Asthma and Immunology (AAAAI) formed an ABPA Com-
mittee, which attempted to determine the incidence of the condition.
Initial results suggested ABPA affected less than 1% of asthma patients,
though without a standard diagnosis and poor reporting the ﬁgure was
speculative.103
A higher incidence of ABPA was found amongst people with cys-
tic ﬁbrosis, which was a rapidly growing group due to the increase in
life expectancy because of improved management of the condition.104
Studies at the end of the 1970s showed that around 10% of children
attending the cystic ﬁbrosis clinics had the symptoms of ABPA.105 How-
ever, fungal allergy was just one of a number of lung infections this
group was vulnerable to and it was far less prevalent than those caused
by bacteria and viruses.106 A study published in 1990 reported that the
main pathogens affecting people with cystic ﬁbrosis were Pseudomonas
aeruginosa (60%) and Staphylococcus aureus (27%), with ABPA in the
range of 0.5–11%.107 However, it was more common in older children
and adults, at around 25%; hence, its importance was likely to grow.108
In 2001, a report by staff at the CDC in Atlanta presented an overview
of mortality from invasive mycoses in the United States from 1980 to
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1997.109 The data they collected showed that ‘deaths in which an infec-
tious disease was the underlying cause, those due to mycoses increased
from the tenth most common in 1980 to the seventh most common
in 1997’, with the annual number of deaths increasing from 1,557 to
6,534. They conﬁrmed that there had been ‘a marked upward trend
in overall mortality due to the invasive mycoses’, and highlighted
the growing importance of immuno-compromising conditions, particu-
larly HIV/AIDS.110 What was interesting was that the regionally speciﬁc
mycoses discussed in this chapter only registered in the summary when
they affected patients with HIV/AIDS, indeed, the disease was ‘a major
determinant of the trend in overall mortality from histoplasmosis’.111
However, the report supported the view that social changes were major
factors in the ﬂuctuating incidence of fungal disease, as with coccid-
ioidomycosis in Arizona, where the increase was due to ‘an inﬂux into
the state of older nonimmune individuals who were susceptible to acute
infection and more likely to manifest symptomatic illness’.112 In other
places, it was not so much the arrival of virgin human soil, but the wider
and more intense circulation of the ‘seeds’ of infection, literally thrown
up by construction and extreme climate events.
In discussing overall mortality, the CDC report conﬁrmed what
doctors’ experience had told them:
The two major factors responsible for the emergence of fungal infec-
tions have been the HIV disease epidemic and the many advances
of modern medicine (including solid organ and bone marrow trans-
plantation) that enable or prolong the survival of critically ill and
susceptible patients. In addition, the aging of the population has
increased the number of susceptible persons.113
To which should be added greater medical awareness, plus new and
more sensitive diagnostic technologies. However, the report showed that
antifungal drugs had reduced mortality in certain groups and from cer-
tain infections; the main exception was aspergillosis, the mycosis most
associated with ‘advances in modern medicine’, which we move on to
in the next chapter.
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